Is Walgreens Getting Enough Out of Q4 Earnings?

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Is Walgreens Getting Enough Out of Q4 Earnings?

© Justin Sullivan / Getty Images

Walgreens Boots Alliance Inc. (NASDAQ: WBA | WBA Price Prediction) reported its fiscal fourth-quarter financial results before the markets opened on Monday. The retailer said that it had $1.43 in earnings per share (EPS) and $34.0 billion in revenue, compared with consensus estimates that called for $1.41 in EPS and $33.89 billion in revenue. The same period of last year reportedly had $1.48 in EPS and $33.44 billion in revenue.

Overall, net sales saw an increase of 1.5% from the year-ago quarter and an increase of 2.6% on a constant currency basis.

The Retail Pharmacy USA segment had fourth-quarter sales of $26.0 billion, an increase of 2.1% year over year. At the same time, Retail Pharmacy International saw sales of $2.7 billion, a decrease of 6.3%.

Pharmaceutical Wholesale had fourth-quarter sales of $5.7 billion, an increase of 3.1%. On a constant currency basis, comparable sales increased 7.9%, led by emerging markets and the United Kingdom.

The company introduced guidance of roughly flat growth in fiscal 2020 adjusted EPS at constant currency rates, with a range of plus or minus 3%. Excluding the impact of lower fiscal 2019 bonus payout, this expected performance represents a year-over-year increase in the mid-single digits. Consensus estimates are calling for $5.96 in EPS and $140.09 billion in revenue for the full year.

[nativounit]

Stefano Pessina, executive vice chair and chief executive, commented:

We are pleased to report fiscal 2019 results in line with our previously stated guidance despite a challenging operating environment. We are also making progress on our four strategic priorities, which we remain confident are positioning us to deliver long-term growth. While we still face headwinds, I am encouraged by the improvement in U.S. comparable sales performance in the second half of fiscal 2019 and our progress in managing costs in order to save to invest to grow. We are introducing guidance for fiscal 2020 adjusted earnings per share, which we expect will be roughly consistent with fiscal 2019 at constant currency rates – very much in line with our expectations.

Shares of Walgreens traded down fractionally early Monday, at $55.20 in a 52-week range of $49.03 to $86.31. The consensus price target is $57.14.

[recirclink id=588057]

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618